Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

Summary

This trial is a multicenter, perspective, non-blinded, randomized controlled phase 3 trial. In order to establish whether the SIB technique can improve the results of twice-daily chemo-RT for patients with LS-SCLC, the investigators will primarily compare survival of patients treated with standard chemotherapy (cisplatin and etoposide) and either SIB twice-daily RT or standard dose twice-daily RT.

Conditions

• Small Cell Lung Cancer Limited Stage
• Radiotherapy

Interventions

RADIATION

SIB

patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy

RADIATION

Standard

patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy

Sponsors & Collaborators

• Sun Yat-sen University

  collaborator OTHER

• Fudan University

  collaborator OTHER

• Xijing Hospital

  collaborator OTHER

• Henan Cancer Hospital

  collaborator OTHER_GOV

• Jilin Provincial Tumor Hospital

  collaborator OTHER

• First Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  collaborator OTHER

• Air Force General Hospital of the PLA

  collaborator OTHER_GOV

• China-Japan Friendship Hospital

  collaborator OTHER

• Peking University Third Hospital

  collaborator OTHER

• Peking Union Medical College Hospital

  collaborator OTHER

• Beijing Hospital

  collaborator OTHER_GOV

• Beijing Chao Yang Hospital

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Peking University First Hospital

  collaborator OTHER

• Anhui Shi, MD

  lead OTHER

Principal Investigators

• Anhui Shi, Doctor · Peking University Cancer Hospital & Institute

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-06-30

Primary Completion

2021-04-30

Completion

2023-01-30

Countries

• China

Study Locations